Research Overview

Research aimed at the clinical application of human iPS cells is approaching at last a decisive stage. To ensure that it progresses smoothly in a timely fashion, cooperation and understanding of our society, especially the research subjects, is necessary. The Fujita Group is committed to investigating issues concerning the Act on the Safety of Regenerative Medicine and cell-based interventions, the use of human iPS cells to create chimeric animals and germ cells, and related questions about domestic and international ethical regulation and government policy, public attitudes, and current practice. We aim to identify and clarify the ethical, social, and legal issues with potential impact on the clinical application of iPS cells and to explore and propose solutions.